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Abstract
Human metapneumovirus (HMPV) is a cause of respiratory tract illness at all ages. In this study the epidemiological and
molecular diversity among patients of different ages was investigated. Between 2000–2001 and 2009–2010, HMPV was
detected in 3% (138/4,549) of samples from outpatients with influenza-like illness with a new, sensitive real-time RT-PCR
assay. Several hundred (797) clinical specimens from hospitalized children below the age of 4 years with acute respiratory
illness were investigated and HMPV was detected in 11.9% of them. Investigation of outpatients revealed that HMPV
infections occurred in individuals of all ages but were most prevalent in children (0–4 years) and the elderly (.60 years). The
most present clinical features of HMPV infections were cough, bronchitis, fever/shivers and pneumonia. About two thirds of
HMPV-positive samples were detected in February and March throughout the study period. Molecular characterization of
HMPV revealed a complex cyclic pattern of group dominance where HMPV subgroup A and B viruses predominated in
general for three consecutive seasons. German HMPV represented all genetic lineages including A1, A2, B1, B2, sub-clusters
A2a and A2b. For Germany, not only time-dependent circulation of lineages and sub-clusters was observed but also co-
circulation of two or three predominant lineages. Two newly emerging amino acid substitutions (positions 223 and 280) of
lineage B2 were detected in seven German HMPV sequences. Our study gives new insights into the molecular epidemiology
of HMPV in in- and outpatients over a time period of 10 years for the first time. It is one of only few long-term surveillance
studies in Europe, and allows comparative molecular analyses of HMPV circulating worldwide.
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Introduction
Human metapneumovirus (HMPV) is a recently detected
paramyxovirus that has been linked to acute respiratory illness
in individuals of all ages [1]. Almost all children by 5 years of age
had been infected with HMPV [1,2]. In children, HMPV
symptomatology is similar to RSV whereas in adults and elderly
subjects HMPV usually causes influenza-like illness (ILI) and colds
[3,4]. More severe courses of disease were preferentially observed
in young children, elderly individuals and immunocompromised
hosts [5].
Genotyping studies have classified circulating HMPV into the
two subgroups A and B [1,6] in which the main differences are
found in the SH and G protein genes [6]. Among HMPV genes a
high level of sequence conservation was found for the F gene that
is assumed to be the principal target for cross-lineage neutralizing
antibody response [6,7]. Within each group the nucleotide and
amino acid identity of the F gene was 94.3–100% and 98.3–100%,
respectively [8]. Between subgroup A and B the identity was 83.0–
83.6% and 94.1–95.4% for the F gene nucleotides and derived
amino acid sequences, respectively [8]. The HMPV F gene codes
for a fusion protein of 539 amino acids in length, harbouring 14
conserved cysteine residues and 3 N-glycosylation sites [9,10].
Based on phylogenetic analyses, HMPV strains can be further
classified into four genetic lineages, named A1, A2, B1 and B2
[11,12] as well as into the previously assigned sub-clusters A2a and
A2b [13]. Intergenotypic comparison of the amino acid sequence
of the F gene identified a number of conserved amino acid residues
specific for each group or lineage [9,11,14].
Since its initial description HMPV has been identified in all five
continents. In temperate climates the highest number of HMPV
infections is diagnosed at the end of winter or in early spring [15–
19], whereas in the subtropics it peaks in spring and summer [20].
Despite the worldwide investigation and detection of HMPV
there is limited information about frequency and lineage
distribution in multiple consecutive seasons. This study describes
for the first time the prevalence, the genetic variability and the
circulation pattern of HMPV over a ten year period in Germany.
Materials and Methods
Ethics Statement
Specimens were taken from patients with influenza-like illness
(ILI) who gave verbal consent for laboratory examination without
documentation. Samples were sent by sentinel practitioners to the
National Reference Centre for Influenza at the Robert Koch
Institute, Germany for acute respiratory infections (ARI) surveil-
lance purposes in Germany. Specimens from hospitalized children
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with ARI were collected by the attending physicians in hospitals.
The analyses of all data were done anonymously. Ethic committee
approval was not required since such a sentinel surveillance is
covered by German legislation (113, 114, Protection against
Infection Act).
Clinical Samples
Two panels of specimen were tested in this study. Specimens
from patients with influenza-like illness (ILI) were collected by the
German National Reference Centre for Influenza at the Robert
Koch Institute, mainly provided by about 150 medical practices
participating in the Influenza Surveillance Scheme (National
German Working Group Influenza). The Influenza-like illness case
definition is a sudden onset of symptoms with at least one of the
following systemic symptoms: fever or feverishness, malaise,
headache, myalgia and at least one of the following respiratory
symptoms: cough, sore throat, shortness of breath and corresponds
to the definition of the European Centre for Disease Prevention
and Control (ECDC). The amount of analysed specimens was
15% of the sample receipt per calendar week in each age group.
All samples were tested negative for influenza virus and RSV by
RT-PCR. Specimens were retrospectively investigated for HMPV
from calendar weeks 41 to 18 (October to the end of April) from
the seasons 2000–2001 to 2009–2010. To describe the circulation
of HMPV in the German population, specimens were analysed
from five different age groups: 0–4 years, 5–15 years, 16–34 years,
35–60 years, .60 years. The second test panel were specimens
from hospitalized children with acute respiratory illness (ARI).
ARI was defined by the National German Working Group
Influenza at the Robert Koch Institute as patients with Bronchitis
or Pneumonia or acute Pharyngitis with or without fever. From
2000–2001 to 2009–2010 two hospitals sent specimens from
patients aged between 0 and 4 years to the National Reference
Centre for Influenza. All specimens were initially tested for
influenza virus and RSV. Only influenza virus- and RSV-negative
samples available from calendar weeks 41 to 18 were investigated
for HMPV. Symptoms and diagnoses for outpatients and
inpatients were requested from medical practices and hospitals
over the whole period; bronchitis was requested for outpatients
(ILI patients) in only three out of ten seasons (2000–2001, 2008–
2009 and 2009–2010) due to changes in the clinical query.
Specimens collected included human nasopharyngeal aspirates
and nasal or throat swabs. Immediately upon arrival swabs were
resuspended or adjusted to 3 ml of sterile minimal essential
medium with HEPES (Gibco BRL, Eggenstein, Germany) and
100 U/ml PEN/STR (Gibco BRL), aliquoted and stored at 2
70uC. Nasopharyngeal aspirates were adjusted to a volume of 3 ml
using the medium described before.
PCR
RNA was extracted from 300 ml culture supernatant using the
MagAttract Viral RNA M48 Kit (Qiagen, Hilden, Germany) and
eluted in 80 ml elution buffer. Alternatively, RNA was extracted
using the MagNA Pure 96 DNA and Viral NA Small Volume Kit
(Roche Deutschland Holding GmbH, Mannheim, Germany) from
200 ml culture supernatant with an elution volume of 50 ml and
using the RTP DNA/RNA Virus Mini Kit (Invitek, Berlin,
Germany) from 400 ml culture supernatant with an elution volume
of 60 ml, respectively. 25 ml of extracted RNA were subjected to
cDNA synthesis applying 200 U M-MLV Reverse Transcriptase
(Invitrogen, Karlsruhe, Germany) in a total volume of 40 ml.
Screening of respiratory samples for HMPV was performed
with a new validated, specific and sensitive two-step real-time RT-
PCR assay described below. To allow for a group-independent
detection, their genetically most conserved region was chosen for
PCR amplification. The specificity of the assays was evaluated
with nucleic acids of various circulating HMPV lineages (A1, A2,
B1 and B2) and other respiratory pathogens including influenza
virus types A and B, human parainfluenzavirus 1–4, human
respiratory syncytial virus A and B, human adenovirus types 2–4,
human echovirus 6, 9, 11 and 19, human coxsackievirus A4 and
B3, human rhinovirus 1B and 37, Streptococcus pneumoniae type 14
and 23, Staphylococcus aureus type 4 and 5 and Chlamydia pneumoniae.
All of the nucleic acids had been previously tested positive with
specific PCR assays. The HMPV assay showed 100% specificity
since no other viral or bacterial respiratory pathogen was detected.
PCR efficiency was determined with the help of plasmids
containing the respective PCR target sequence. The assay
displayed a dynamic range from 106 to 101 target copies with a
high standard curve correlation of R2 = 0.987. For determination
of the reproducibility intra- and interassay variability was done
using plasmids. The range of the threshold cycle (CT) values varied
between 0.09 and 0.22 CT for the intraassay and the interassay
variation was between 0.41 and 0.66 CT. The 95% detection
probability (Probit analysis) was found to be 10.1 genome
equivalents per reaction.
Clinical samples were analyzed by our new developed real-time
PCR on the ABI PRISMH 7500 Sequence Detection System
(Applied Biosystems, Weiterstadt, Germany) or LightCyclerH 480
Real-Time PCR System (Roche Deutschland Holding GmbH),
respectively in a total reaction volume of 25 ml. The reaction
contained 16PCR buffer (200 mM Tris-HCl [pH 8.4], 500 mM
KCl), 5 mM MgCl2 (Invitrogen), 0.1 mM dNTP (Invitrogen) with
dUTP (GE Healthcare, Munic, Germany), 0.5 U Platinum Taq
DNA polymerase (Invitrogen), primers (Metabion, Martinsried,
Germany): HMPV F S (gCTCCgTAATYTACATggTgCA);
HMPV F S1 (gAAgCTCYgTgATTTACATggTYCA); HMPV F
AS (gACCCTgCARTCTgACAATACCA); HMPV F AS1
(AgTKgATCCTgCATTTTTACAATACCA) and probes: (Ap-
plied Biosystems, Foster City, United States and Tib Molbiol,
Berlin, Germany) HMPV F TMGB (F-CCYTgCTggATAg-
TAAAA-MGB); HMPV F TMGB1 (F-CCTTgTTggATAAT-
CAA-MGB) in differing concentrations, and 3 ml of cDNA.
Amplification was carried out at 95uC for 5 min, followed by 45
cycles at 95uC for 15 s and 60uC for 30 s.
PCR for Molecular Analysis of the F Protein Gene and
Sequencing
A number of 95 of HMPV-positive samples were selected for
partial amplification of the F protein gene by either external or
semi-nested PCR. The first amplification was performed with 5 ml
of cDNA in a 50 ml reaction by using 250 nM of each of the
primers (Metabion) HMPV-3637-F (gTYAgCTTCAgTCAATT-
CAACAgAAg) [13], HMPV-4192-R1 (CAgTgCAACCATACT-
gATRggATg) and HMPV-4192-R2 (TAgTgCAACCATACT-
gATRgggTg), 100 mM deoxynucleoside triphosphates, 3 mM
MgCl2, 1 U Platinum Taq DNA polymerase (Invitrogen) and
PCR buffer (200 mM Tris-HCl [pH 8.4], 500 mM KCl).
Amplification was carried out at 94uC for 5 min, followed by 40
cycles at 94uC for 30 s, 60uC for 30 s, and 72uC for 45 s, with a
final extension at 72uC for 10 min. The amplified products of
555 bp were analyzed by electrophoresis on a 1.5% agarose gel. In
the case of negative results, 5 ml of the external PCR reaction were
used for semi-nested PCR which was performed in a 50 ml
reaction with 250 nM each of the primer HMPV-3637-F and
HMPV-4164-R (CCTgTgCTRACTTTgCATggg), respectively.
The cycling protocol was the same as for the external PCR except
for the annealing temperature which was 66uC. The nested
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amplicons of 527 bp were visualized by agarose gel electrophoresis
as well. The PCR products were purified either directly with
QIAquick PCR Purification Kit (Qiagen, Hilden, Germany) or
from agarose gels with JETquick spin column technique
(Genomed, Löhne, Germany) according to the manufacturer’s
instructions. Purified PCR products were cycle sequenced in the
forward and the reverse directions with primer pairs previously
used for external and semi-nested PCR, respectively, in a 31306l
Genetic Analyzer (Applied Biosystems) by using the BigDye
Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems).
Phylogenetic Analysis
A multiple sequence alignment was compiled from a part
(473 nt) of the FI subunit of the F gene using ClustalW in the
Bioedit version 7.0.9 [21]. Maximum likelihood tree was
constructed by using Geneious 5.0.4 [22]. The reliability of the
branching order was estimated by performing 1,000 bootstrap
replicates with the HKY85 model. Phylogenetic analysis included
representative sequences of the described HMPV lineages and
subgroups. GenBank accession numbers and the country of
isolation of the reference sequences are given in the supporting
information (Table S1). The tree was manually edited in Corel
Draw 12 program.
Pairwise nucleotide and amino acid distances within and
between groups were calculated using MEGA and determined
distances described in terms of mean and standard deviation.
Nucleotide Sequence Accession Numbers
The GenBank accession numbers of the nucleotide sequences
obtained in the present study are HQ456546 to HQ456640.
Statistical Analysis
The SPSS software version 17.0 was used for statistical analysis
of data. Differences between mild and intensive HMPV seasons
were statistically analyzed using the chi-squared test and frequency
of HMPV-positive inpatients and outpatients using the unpaired t-
test. Probit analysis was undertaken to determine the assay’s limit
of detection (95% confidence interval, CI). Odds ratio (OR) and
CI were calculated according to diagnosis and symptoms. OR was
calculated as the ratio of the odds of a diagnosis/symptom in
HMPV-positive patients to the odds of it in HMPV-negative
patients. HMPV-negative patients belonged to the study popula-
tion and were therefore symptomatic patients with ILI or ARI
without a detectable HMPV infection.
Results
Frequency and Distribution of HMPV
During the ten-year study period from seasons 2000–2001 to
2009–2010 more than 4,500 clinical specimens were tested by a
newly developed and validated sensitive and specific HMPV in-
house real-time RT-PCR assay. For generation of population
based data, a panel of specimens from patients with ILI was
analysed. Sixty-six (48%) of the ILI specimens were from females
and the median age of HMPV-positive specimens was 7 years
(range: 0–88 years). Specimens investigated herein were obtained
from patients of five different age groups (0–4 years, 5–15 years,
16–34 years, 35–60 years, and .60 years) to elucidate the
occurrence of HMPV in the German population. On average 3%
(138) were found to be positive (Table 1). HMPV infections were
detected in patients from all age groups but were most common
among children between 0 and 4 years (6.9%) and individuals
above 60 years (4.6%). Whereas in children between 0 and 4 years
HPMV was found in every season with the lowest positive rate of
2.2% and the highest rate of 16.8%, in adults .60 years the rate of
positive samples peaked in every other season being either low
(0%–2%) or high (7.5%–14.2%) (Table 1). The virus was detected
in every season. Season 2003–2004 (6.8%) and season 2009–2010
(4.7%) were characterized by a very intensive circulation of
HMPV in Germany (estimated using chi-square test, P,0.001)
(Table 1). As approximately two thirds of positive HMPV samples
were detected between calendar weeks 3 and 16, we concluded
that HMPV peak activity occurred mainly in February and
March.
Frequency of HMPV in Hospitalized Paediatric Patients
Compared to Outpatients
To study the frequency of HMPV and its impact in children
under the age of 4 years a panel of 797 clinical specimens from
hospitalized children (,4 year) with ARI were collected from
seasons 2000–2001 to 2009–2010. PCR assay revealed the
presence of HMPV in 11.9% (95) of the inpatient samples
(Table 2). Frequency of HMPV was in the range of 0% and 32.8%
with an intensive circulation of HMPV in the seasons 2001–2002
(32.3%) and 2009–2010 (32.8%) (estimated using chi-square test,
P = 0.001). Whereas in the seasons 2000–2001 to 2005–2006 the
proportion of positive samples tended to increase and decrease
from one to the next season, the rate remained relatively high from
season 2005–2006 to 2009–2010.
In comparison to outpatients of the same age, frequency of
HMPV in inpatients (11.9%) was about twice as high as in
outpatients (6.9%). The proportion of HMPV tended to be higher
in inpatients, whereas significant differences were only determined
for the seasons 2001–2002 (P#0.001), 2005–2006 (P#0.01) and
2009–2010 (P,0.5) (Table 2).
Clinical Diagnosis Associated with HMPV
The most frequent symptoms among all ILI cases positive for
HMPV were cough (94%), sudden onset (92%), fever/shivers
(88%) and muscle pain/headache (72%) (Table 3). Bronchitis
(17%), fever (17%), or pneumonia (7%) were seen less frequently.
The ORs for diagnoses and symptoms associated with positivity
for HMPV are depicted in Table 4. HMPV infections were
associated with cough (OR 4.54; 95% CI = 2.22 to 9.31), fever/
shivers (OR 2.01; 95% CI = 1.21 to 3.36), bronchitis (OR 2.76;
95% CI = 1.43 to 5.34), and pneumonia (OR 3.39; 95% CI = 1.67
to 6.87). Despite the general association of HMPV with these
symptoms and diagnoses there were differences with regard to the
age. Cough (OR 9.96; 95% CI = 2.41 to 41.15) and bronchitis
(OR 2.70; 95% CI = 1.09 to 6.66) were associated with HMPV in
patients younger than 4 years. Fever/shivers (OR 4.29; 95%
CI = 1.26 to 14.58) in patients older than 60 years (Table 4).
The comparison of children (0–4 years) with HMPV under
hospitalized or ambulant conditions showed that cough (OR 2.59;
95% CI = 1.53 to 4.38) is associated with HMPV in inpatients
whereas in outpatients cough (OR 9.96; 95% CI = 2.41 to 41.15),
fever/shivers (OR 2.26; 95% CI = 1.01 to 5.07) and bronchitis
(OR 2.70; 95% CI = 1.09 to 6.66) were associated with HMPV
(Table 5).
Genetic Diversity of HMPV in Germany
Phylogenetic analysis was conducted on German HMPV
sequences of 477 nt of the F gene (Figure 1). During the 10-year
study all of the known HMPV lineages and sub-clusters which are
A1, A2, B1, B2, A2a and A2b were detected. Most of the
sequences belonged to HMPV subgroup A and were predomi-
nantly found to be sub-clusters A2b. Furthermore, there were
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German HMPV sequences which were identical or closely related
to sequences from Singapore (SIN06-NTU84), Japan (JPS03-187,
JPS03-180, JPS03-194), Beijing/China (BJ1887), The Netherlands
(NL/17/00) and Canada (CAN97-83), Tennessee/USA (TN/03–
29), Liverpool/UK (LIV03-180, LIV04-873, LIV04-789) or Egypt
(EG/332(NS)/08 and EG/318(S)/08). The majority of these
sequences were related to sequences of the same season. Some
clusters in lineages B1 and B2, as well as in sub-cluster A2b were
only presented by German viruses. One cluster is supported by a
high bootstrap value of 99.1%. Moreover, multiple identical
sequences were identified during the same season [e.g. GER/
0738/01-02(1), GER/1036/01-02(2), GER/1368/01-02(2),
GER/1801/03-04(1), GER/1513/03-04(1), GER/0711/03-
04(5), GER/5492/04-05(1), GER/1558/06-07(1), GER/1269/
06-07(1), GER/0562/07-08(1), GER/3868/09–10(1), GER/
3044/09-10(1), GER/3272/09-10(1)]. Limited identical sequences
were found in consecutive [GER/1036/01-02(2) and GER/3810/
02-03, GER/1370/04-05 and GER/0394/05-06, GER/0562/
07-08(1) and GER/3379/09-10] or distant seasons [GER/0755/
01-02 and GER/1558/06-07(1)].
Seasonal Circulation Pattern of HMPV Lineages and Sub-
clusters
With the exception of the seasons 2000–2001 and 2006–2007,
all seasons were characterized by the circulation of HMPV A2.
Only A2b circulated in all seasons as indicated above (Figure 2).
Sub-cluster A2a viruses circulated from 2001–2002 to 2003–2004
and reappeared in the season 2007–2008. Epidemic seasons are
further characterized by the recurrent appearance and disappear-
ance of lineage B2, whereas lineage A1 and B1 were only present
until seasons 2002–2003 and 2005–2006, respectively.
Genetic Variability/Diversity of HMPV
Nucleotide distance within genetic lineages and sub-clusters
ranged between 0.0056 and 0.0169, whereas the lowest differences
were observed for lineage A1 and A2. As expected, nucleotide
distance was highest between lineages and sub-clusters where it
Table 1. Frequency of HMPV, by age group and epidemic season.
Frequency of HMPV in % (positive/analyzed sample)
Epidemic season (yr) Total 0–4 years 5–15 years 16–34 years 35–60 years .60 years
2000–2001 1.2 (4/330) 3.1 (3/97) 2.0 (1/49) 0 (0/63) 0 (0/72) 0 (0/49)
2001–2002 3.5 (15/429) 2.2 (1/44) 4.1 (5/120) 2.0 (2/100) 2.0 (2/99) 7.5 (5/66)
2002–2003 2.5 (11/440) 8.0 (6/75) 1.8 (2/109) 1.5 (2/127) 1.0 (1/94) 0 (0/35)
2003–2004 6.8 (25/365) 12.0 (9/75) 6.2 (6/97) 1.5 (1/63) 4.4 (3/67) 9.5 (6/63)
2004–2005 1.2 (10/803) 3.0 (4/133) 0.4 (1/260) 1.3 (2/149) 0.5 (1/171) 2.2 (2/90)
2005–2006 3.6 (12/333) 3.5 (2/57) 0.7 (1/126) 5.6 (3/54) 1.6 (1/61) 14.2 (5/35)
2006–2007 2.5 (11/434) 7.4 (10/136) 0 (0/127) 0 (0/72) 1.8 (1/57) 0 (0/42)
2007–2008 3.8 (16/411) 10 (6/60) 3.0 (4/132) 1.4 (1/68) 1.9 (2/103) 6.3 (3/48)
2008–2009 2.2 (12/540) 5.4 (5/93) 2.0 (3/149) 0.9 (1/108) 2.3 (3/130) 0 (0/60)
2009–2010 4.7 (22/464) 16.8 (13/77) 3.0 (5/164) 0 (0/94) 1.1 (1/93) 8.3 (3/36)
Total 3.0 (138/4549) 6.9 (59/847) 2.1 (28/1333) 1.3 (12/898) 1.6 (15/947) 4.6 (24/524)
doi:10.1371/journal.pone.0088342.t001











2000–2001 25 0 0 97 3 3.1
2001–2002 34 11 32.3 44 1 2.2
2002–2003 71 1 1.4 75 6 8.0
2003–2004 117 17 14.5 75 9 12.0
2004–2005 140 7 5.0 133 4 3.0
2005–2006 97 17 17.5 57 2 3.5
2006–2007 95 8 8.4 136 10 7.4
2007–2008 90 6 6.7 60 6 10
2008–2009 64 7 10.9 93 5 5.4
2009–2010 64 21 32.8 77 13 16.8
Total 797 95 11.9 847 59 6.9
doi:10.1371/journal.pone.0088342.t002
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was in the range of 0.0269–0.1478. Within and between lineages
and sub-clusters, nucleotide distances were higher compared to the
observed amino acid distances, which were 0.0000–0.0065 within
and 0.0000–0.0363 between lineages and sub-clusters, respective-
ly.
Further the translated sequences were compared towards amino
acid changes. Sequence comparisons identified the five amino acid
residues (positions 233, 286, 296, 312 and 348) specific to each
lineage described by Yang et al., 2009 [9]. In addition, single
amino acid substitutions were found for the lineages A2
(Asn298Ser) and B1 (Val231Ala, Ser347Thr). The highest amino
acid variability was observed for sequences of the lineage B2.
Herein, three variations were present: Thr223Asn (7/21 sequenc-
es), Asp280Asn (7/21 sequences), and Asn358Lys (1/21 Sequenc-
es). Phylogenetic analysis (Figure 1) revealed that these sequences
clustered separately and were closely related to sequences from
Egypt (EG/332(NS)/08 and EG/318(S)/08).
Discussion
To study the molecular and epidemiological features of HPMV
in Germany a retrospective long-term study was conducted. More
than 4,500 clinical specimens of patients with ILI were collected
by general practitioners over a period of ten consecutive seasons
(2000–2001 to 2009–2010), and HMPV was detected in 138 (3%)
respiratory samples. HMPV infections occurred in individuals of
all ages but tend to be most frequent in children aged between 0
and 4 years and the elderly (.60 years), which is consistent with
previous reports [23]. In a comparable system of national
virological surveillance from England and Wales, sentinel general
practices detected HMPV in 2.2% of samples collected from
patients of all ages with ILI during the winter of 2000–2001 [15].
In contrast to our study, detection of HMPV in northern Greece
was on average associated with a twofold higher prevalence
(6.05%) in specimens from ILI-patients during the influenza
seasons 2005–2006, 2006–2007 and 2007–2008 [24]. But as
observed for Germany, in the Greek population HMPV was
determined in all age groups, with the highest prevalence in
children aged between 0 and 5 years. Studies indicated that
HMPV has infected almost all children by the age of 5 years [1,2].
HMPV infection is not restricted to the very young children but
also occurs in adults and elderly subjects [3]. Despite the HMPV
infection in childhood, new infections may occur throughout life
Table 3. Comparison of the clinical features among patients with HMPV (outpatients with ILI) in different age groups.
Variables Number of positive samples (%)
Age group total (n = 138) 0–4 years (n = 59) 5–15 years (n = 28) 16–34 years (n = 12) 35–60 years (n = 15) .60 years (n = 24)
Age (median) 7 2 7 31 47 67
Females 66 23 13 8 7 15
Diagnosis/Symptom
Cough 130 (94) 54 (96) 26 (93) 12 (100) 13 (87) 22 (92)
Sudden onset 127 (92) 51 (91) 25 (89) 12 (100) 15 (100) 23 (96)
Fever/Shivers 121 (88) 49 (88) 27 (96) 8 (67) 13 (87) 21 (88)
Muscle pain/Headache 100 (72) 28 (50) 25 (89) 11 (92) 14 (93) 21 (88)
Bronchitisa 17 (46) 10 (48) 3 (38) 0 1 (25) 3 (100)
Fever 23 (17) 9 (16) 6 (21) 0 1 (7) 7 (29)
Pneumonia 9 (7) 3 (5) 2 (7) 0 1 (7) 3 (13)
aBronchitis was requested in three out of ten seasons (number of HMPV-positive samples correlated with bronchitis n = 37, within age groups: 0–4 years n = 21; 5–15
years n = 8; 16–34 years n = 1; 35–60 years n = 4; .60 years n = 3).
doi:10.1371/journal.pone.0088342.t003
Table 4. Odds ratio of HMPV-positive patients with influenza-like illness (outpatients) according to diagnoses and symptoms.
total 0–4 years 5–15 years 16–34 years 35–60 years .60 years
Diagnosis/
Symptom OR 95% CI OR 95% CI OR 95% CI OR 95% CI OR 95% CI OR 95% CI
Cough 4.54 2.22, 9.31 9.96 2.41, 41.15 3.55 0.84, 15.05 2 2 1.81 0.41, 8.09 2.85 0.66, 12.33
Sudden onset 1.13 0.61, 2.11 1.52 0.68, 3.42 0.47 0.14, 1.60 2 2 2 2 3.32 0.44, 24.98
Fever/Shivers 2.01 1.21, 3.36 2.26 1.01, 5.07 5.03 0.68, 37.24 0.61 0.18, 2.03 1.96 0.43, 8.65 4.29 1.26, 14.58
Muscle pain/
Headache
0.80 0.55, 1.17 1.19 0.70, 2.01 1.77 0.53, 5.92 1.71 0.22, 13.34 2.64 0.34, 20.25 2.11 0.62, 7.22
Bronchitisa 2.76 1.43, 5.34 2.70 1.09, 6.66 3.32 0.77, 14.31 0 2 0.94 0.10, 9.20 0 2
Fever 1.04 0.66, 1.64 0.74 0.36, 1.54 1.70 0.68, 4.26 0 2 0.36 0.05, 2.72 2.33 0.94, 5.82
Pneumonia 3.39 1.67, 6.87 1.51 0.44, 5.13 5.83 1.28, 26.53 0 2 3.10 0.39, 24.66 3.62 0.99, 13.19
OR: odds ratio; CI: confidence interval,
aBronchitis was requested in three out of ten seasons.
doi:10.1371/journal.pone.0088342.t004
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due to incomplete protective immune responses and/or acquisi-
tion of a new lineage [5]. These findings may explain intense
frequency in children and the elderly observed in our study.
Symptoms and diagnoses primarily associated with HMPV-
positive specimens (ILI) in this study were cough and bronchitis as
reported previously [3,20,25]. The assessment of odds ratio
showed, that in children (,4 years with ILI) cough and bronchitis
were associated with HMPV infection. In the age group 5–15
years, HMPV-positive patients had a higher chance to develop
pneumonia. Fever/shivers seems to be associated with the elderly
(.60 years old) infected with HMPV. However, it was reported
that older patients (66–83.2 years old) were less likely to report
fever in contrast to adults with an influenza virus infection [26].
Our data support the assumption that clinical manifestations of
HMPV infections in adults are not limited to few specific clinical
features, but vary from asymptomatic to mild upper RTI
symptoms and severe pneumonia, respectively [27]. The compar-
ison of inpatients and outpatients younger than 4 years old
revealed that cough is associated most frequently with HMPV-
positives of both cohorts, whereas fever/shivers and bronchitis are
very common symptoms and diagnoses in HMPV-outpatients.
Pneumonia is a frequent diagnosis of hospitalized children positive
for HMPV [28–30], which did not correlate to our calculated odds
ratios. This suggests that, compared to adults, children do not
show specific clinical features for a HMPV-associated disease.
Most of the available data on HMPV infections are from studies
of young hospitalized children, in which the virus causes acute
respiratory illness (ARI) [31–34]. HMPV has been detected in 1–
17% of ARI cases [23,35–38]. In the present study hospitalized
pediatric patients (0–4 year) with ARI were compared to children
at the same age with ILI as outpatients. HMPV was detected in
11.9% of specimens from inpatients younger than 4 years in
comparison to 6.9% infections in outpatients.
By trend, there was a biennial pattern in seasons with low and
high HMPV-positive rates in hospitalized patients from season
2000–2001 to 2006–2007 within the range of 1.4% to 32.3%. Two
earlier studies from Germany analysed HMPV in hospitalized
children, reporting on similar findings [13,39]. These data
revealed that a season (2001–2002) with a high (17.5%) positive
rate was followed by a season (2002–2003) with a low (1.9%) and
again by a season (2003–2004) with a high (7.9%) detection rate.
In the subsequent seasons the HMPV rate remained in a lower
range (6.7% to 10.9), but 2009–2010 there was an increase to
32.8%. Interestingly, the data of HMPV infection rate in
outpatients was less distinct than in inpatients. The rates were
high in season 2003–2004 (12.0%) and in season 2009–2010
(16.8%). In season 2009–2010 the amount of the positive rate was
twice lower in inpatients than in outpatients. Whereas in season
2001–2002 the prevalence of HMPV in inpatients was at a high
level with 32.3%, the positive rate in outpatients was at a low level
of 2.2%. A reason for this inhomogeneity remains unclear and
may be explained by sampling bias or by virulence factors of
HMPV. In our study, the sampling bias was reduced by the
selection of related amounts of samples over the whole study
period versus outpatients and inpatients. Another possible
explanation regards the virulence of HMPV. The assumption
that HMPV-positive children in the age group of 0–4 years
showed severe symptoms and diagnoses and were therefore
hospitalized instead of being attend to pediatrician might be an
explanation for the high positive rate of inpatients. The HMPV-
sequences of the F protein in the season 2001–2002 provide no
indication of a cluster with virus variants which may be correlated
to changes in the virulence. In addition, we could not find a
correlation between a statistically high HMPV prevalent season
and a dominance of an antigenic subgroup because in two seasons
subgroup A was predominant and in one season it was subgroup
B. Seasonal variation of HMPV was observed in other studies with
hospitalized patients, like Austria (3–10.1%), Sweden (0.8–5.9%),
Italy (7–43%) or South Africa (3.7–9.6%) [23,40–42]. Further
studies are necessary to explain the complexity of HMPV
frequency rates.
About two thirds of HMPV-positive samples were detected in
February and March, indicating that in Germany HMPV
circulated primarily during the late winter and early spring, as
observed for other countries of the temperate zone [15–19]. In
Austria, a clear biennial pattern of alternating winter (peak
activities between December and February) and spring (peak
activities between April and June) activity was observed whereas a
Table 5. Comparison of odds ratio from HMPV-positive inpatients and outpatients (children 0–4 years old) according to diagnoses
and symptoms.
Inpatients (n = 797) Outpatients (n = 847)
No. of positive
samples (%) (n = 95) OR 95% CI
No. of positive
samples (%) (n = 59) OR 95% CI
Age/Years (median) ,1 2
Females 33 23
Diagnosis/Symptom
Cough 76 (80) 2.59 1.53, 4.38 54 (96) 9.96 2.41, 41.15
Sudden onset 29 (31) 0.93 0.59, 1.48 51 (91) 1.52 0.68, 3.42
Fever/Shivers 24 (25) 1.28 0.78, 2.10 49 (88) 2.26 1.01, 5.07
Muscle pain/Headache 1 (1) 0.56 0.07, 4.36 28 (50) 1.19 0.70, 2.01
Bronchitisa 42 (44) 1.45 0.94, 2.24 10 (48) 2.70 1.09, 6.66
Fever 21 (22) 1.27 0.76, 2.14 9 (16) 0.74 0.36, 1.54
Pneumonia 30 (32) 1.49 0.93, 2.38 3 (5) 1.51 0.44, 5.13
OR: odds ratio; CI: confidence interval,
aBronchitis in outpatients was requested in three out of ten seasons (number of HMPV-positive samples n = 21, number of HMPV-positive specimens with bronchitis
n = 10).
doi:10.1371/journal.pone.0088342.t005
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Figure 1. Phylogenetic tree of partial F gene fragments of German HMPV. The tree was constructed using the maximum likelihood
estimation with 1,000 replicates through Geneious 5.0.4. Avian metapneumovirus C (AMPV C) was included in the analysis and used as outgroup.
Reference sequences (supporting information Table S1) representing the different HMPV genetic lineages were additionally included in the analysis.
German HMPV sequences are shown in boldface. Nomenclature for German sequences uses a letter code representing the country of detection (e.g.,
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significantly higher prevalence of HMPV was determined in
seasons with winter activity and vice versa [40]. These findings are
supported by a study from China in which the authors found
HMPV infection peaks between November and February and
April to June [28]. HMPV epidemics twice a year were not
determined in our study because the sampling was done only
during the cold season. With reference to our data, there were only
two seasons (2003–2004 and 2009–2010) with a statistically
significant intense circulation of HMPV as shown by the
population based study. The seasonality of HMPV infection is
not fully understood but it can be affected by climate [28] and the
timing of seasonal epidemics may vary by region [43].
Phylogenetic analysis of the HMPV F gene of viruses circulating
in Germany revealed a complex and dynamic circulation of all
HMPV subgroups (A and B) and lineages (A1, A2, B1 and B2) in
the ten years study interval. In nine of ten seasons HMPV
subgroup A or B predominated the season. In season 2007–2008
both groups were simultaneously existent (Fig. 2). Such a complex
pattern was also found in a long-term study from the United States
[9]. Predominance of subgroups A or B, respectively, was observed
both for a single season (1982, 1983, 1987, 1993, 1994, 2000,
2001, and 2003) and a maximum of three consecutive seasons
(1984–1986, 1989–1991, and 1996–1998). Besides, there were
seasons with a co-dominance of HMPV subgroups A and B (1988,
1992, 1995, and 1999). Thus, for the United States no regular
cyclic pattern could be determined. German HMPV represented
all previously described sub-clusters, and co-circulation of mainly
two or three sub-clusters was observed. Co-circulation of two or
more sub-clusters is not unusual as similar findings have been
reported from countries all over the world, e.g. United States [9],
Australia [12,44], United Kingdom [45], Croatia [36], Japan [46],
China [47], South Korea [48], Brazil [49] and France [50]. It was
suggested, that outbreaks of HMPV subgroups and sub-clusters
appear to be a local phenomenon unlike to influenza, which
spreads across the continents with two or three viruses [30]. Long-
term studies of HMPV for more than two to three seasons have
rarely been reported. Only one study in France described the
situation of HMPV infections in hospitalized children over a time
period of seven years [50]. Therefore it remains difficult to map
the European circulation pattern of HMPV. The reason of HMPV
circulation complexity remains unclear but it may complicate the
challenges for the development of HMPV vaccines.
The analysis of sequence diversity for the F fragment showed
that nucleotide distance within lineages/sub-cluster was 0.0056–
0.0169. The nucleotide distance was higher than the correspond-
ing amino acid distance (0.0000–0.0065), which was explained by
a hypothesis that functional constraints on paramyxovirus fusion
proteins prevent dramatic amino acid changes [9]. Within one
epidemic season circulation of multiple identical isolates was
observed in Germany, implicating that HMPV infections occur
due to highly similar viruses within one season. Detection of
identical sequences in consecutive seasons is rare. Sequences from
German isolates were identical to closely related viruses isolated in
distant regions suggesting that human travelling behaviour might
influence the evolution of new epidemic viruses in distant places.
‘‘GER’’ represents Germany) followed by the patient number and season in which the virus was detected. In the case of identical sequences only one
sequence is shown, whereas the number in brackets indicates the number of additional identical sequences. The lineages and sub-clusters are
indicated to the right of the figure. Only bootstrap values greater than 65% are displayed at the branch nodes.
doi:10.1371/journal.pone.0088342.g001
Figure 2. Seasonal circulation of HMPV lineages and sub-clusters in Germany. The number of samples is shown on the abscissa.
doi:10.1371/journal.pone.0088342.g002
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The amino acid alignment of all German HMPV F sequences
showed five amino acid substitutions at positions 233; 286; 296;
312; and 348 that can be used as signature amino acids to
differentiate between HMPV subgroups A and B [9]. Whereas no
specific amino acid residue was found to discriminate between
sequences from lineages A1 and A2, there was one specific
substitution at position 296 distinguishing between lineages B1
(Asn) and B2 (Asp) [9]. Specific amino acid substitutions are not
limited to German sequences and were also specific to sequences
from the United States [9], The Netherlands [11] or Canada [14].
Sequence analysis of the complete F gene determined a number of
amino acid residues distinct to a certain subgroup or lineages,
however, the biological importance of these variations is not clear
[9]. Moreover, we observed two amino acid substitutions which
were specific for seven German HMPV of lineage B2. These
viruses cluster separately with sequences from Egypt possessing the
same substitutions [51]. Prospectively, it has to be monitored if
those viruses develop into a new sub-cluster in lineage B2.
In summary, the present study provides for the first time data on
HMPV infections in in- and outpatients of the German
population. HMPV was detected in individuals of all ages during
ten consecutive seasons, mainly in February and March. HMPV
infections were associated with cough, fever/shivers and pneumo-
nia, respectively. Molecular characterization of HMPV revealed a
complex circulation pattern of group dominance where HMPV
groups A or B viruses predominated in general for three
consecutive seasons. German HMPV represented all of the
previously described lineages and sub-clusters. Next to the
existence of a time-dependent circulation of subgroups and sub-
clusters co-circulation of mainly two or three lineages was
observed. Furthermore, nucleotide diversity was greater than
amino acid diversity within lineages, suggesting that HMPV does
not evolve rapidly which is an important feature for the
development of monoclonal antibodies and vaccine strains. Our
HMPV data present the first long-term study in Germany in in-
and outpatients. It is one of only few in Europe and therefore it
provides new insights into the epidemiology and genetic diversity
of HMPV in Europe and, moreover, allows comparative analyses
of worldwide circulating HMPV.
Limitations of the Study
Like most published studies on HMPV, the present study has
limitations. This includes potential sampling biases that may affect
accurate risk factor modelling. In this study, the rate of HMPV-
positives was in general higher in inpatients than in outpatients.
This observation might be explained by the different selection
criterion of these groups. Samples from inpatients come from
patients with ARI, which is described to be similar to HMPV in
children [16,33,43]. In contrast, samples from outpatients were
taken from patients with ILI. Influenza-like illness is preferentially
a clinical manifestation of HMPV in adults but not in children or
the elderly [3]. As only outpatients presenting with ILI symptoms
were sampled, most acute respiratory infections that occur outside
this surveillance definition are unsampled, thereby increasing the
likelihood of underestimation HMPV as a cause of ARI in children
and the elderly. The query of symptoms and diagnoses was not
consistent for bronchitis in ILI patients (outpatients) because the
questionnaire was changed during the ten year sampling period in
this aspect. Nevertheless, the rate of bronchitis was high and our
data may underestimate the overall rate of bronchitis in HMPV-
positive outpatients, particularly because no data of bronchitis in
outpatients were collected in the season 2003–2004 with an
intensive circulation of HMPV.
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